Albert Einstein College of Medicine

University of Toronto

US Government As Represented by the Secretary of the Army

Jonathan R Lai

Julia Frei

Sachdev Singh Sidhu

Kartik Chandran

Elisabeth K Nyakatura

John M Dye

Gang Chen

Samantha Zak

Evripidis Gavathiotis

Jayne F Koellhoffer

Anna Z Wec

Steven Craig Almo

Jacqueline Michele Achkar

Margaret Kielian

Elise Ishida

Daniel Hofmann

Nina Liu

Tingting Chen

Jose Quiroz

Ryan Malonis

Jayne F Koelhoffer

Alex Stewart

Provided are high affinitycapsule-specific antibodies and fragments thereof, as well as methods of use and devices employing such antibodies and/or fragments.

High-affinitycapsule-specific human monoclonal antibody

Provided are high affinity anti-alphavirus antibodies or alphavirus-binding fragments thereof, as well as methods of use and devices employing such antibodies and/or fragments. Further provided are complementarity determining region (CDR) sequences of variable domain light chain (VL) and variable domain heavy chain (VH) sequences, and the methods of using the high affinity anti-alphavirus antibodies for treating different types of alphavirus infections.

Antibodies or antibody-fragments thereof targeting alphaviruses, and compositions and methods comprising same

Methods for treating and for preventing filovirus infections are disclosed, as well as compositions therefor.

Multi-specific antibodies for cross-neutralization of multiple filovirus glycoproteins

Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD- L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.

Engineered PD-1 variants

Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.

Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.

Synthetic antibodies to BAX and uses thereof

Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick C1 (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.

Methods of treating filovirus infections utilizing bispecific antibodies and fusion proteins that bind EBOV and NPC1

The present invention addresses a need for antibodies useful for filovirus infections.

Filovirus antibody

Specific Dengue virus glycoprotein subunit E DIII variants and their uses in preventing and treating Dengue virus infection are disclosed.

Dengue virus glycoprotein E DIII variants and uses thereof

The present invention addresses a need for improved treatments for filovirus infections. This invention provides an isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region. Also provided is a method of treating and/or inhibiting a filovirus infection in a subject comprising administering to the subject an amount of any of the antibodies described herein, or an amount of an antigen-binding fragment thereof. Also provided is composition comprising any of the antibodies described herein, or or an amount of an antigen-binding fragment thereof. In an embodiment, the composition comprises a pharmaceutically acceptably carrier.

Therapy for filovirus infection

Methods for treating and for preventing Filovirus infections are disclosed, as well as compositions therefor.

Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick CI (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.

Growing community of inventors

Dobbs Ferry, NY, United States of America

Jonathan R Lai